Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Expression pattern of co-inhibitory molecules on CMV-specific T-cells in lung transplant patients.

Bessa V, Sun M, Meier M, Zeng Y, Xu S, Dolff S, Sommerwerck U, Korth J, Taube C, Aigner C, Kamler M, Kribben A, Lindemann M, Witzke O, Wilde B.

Clin Immunol. 2019 Sep 6;208:108258. doi: 10.1016/j.clim.2019.108258. [Epub ahead of print]

PMID:
31499181
2.

HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant.

Rohn H, Michita RT, Schramm S, Dolff S, Gäckler A, Korth J, Heinemann FM, Wilde B, Trilling M, Horn PA, Kribben A, Witzke O, Rebmann V.

Cells. 2019 Aug 7;8(8). pii: E847. doi: 10.3390/cells8080847.

3.

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry.

Korth J, Sertznig H, Moyrer S, Doevelaar AAN, Westhoff TH, Babel N, Witzke O, Kribben A, Dittmer U, Widera M.

J Vis Exp. 2019 Jul 13;(149). doi: 10.3791/59755.

PMID:
31355784
4.

Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants.

Gäckler A, Dolff S, Rohn H, Korth J, Wilde B, Eisenberger U, Mitchell A, Kribben A, Witzke O.

BMC Nephrol. 2019 May 14;20(1):167. doi: 10.1186/s12882-019-1340-z.

5.

B-cell dynamics during experimental endotoxemia in humans.

Brinkhoff A, Zeng Y, Sieberichs A, Dolff S, Shilei X, Sun M, Engler H, Benson S, Korth J, Schedlowski M, Kribben A, Witzke O, Wilde B.

Biosci Rep. 2019 May 17;39(5). pii: BSR20182347. doi: 10.1042/BSR20182347. Print 2019 May 31.

6.

Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients.

Dornieden T, Wilde B, Korth J, Werner K, Horn PA, Witzke O, Lindemann M.

J Immunol Res. 2019 Feb 25;2019:3926175. doi: 10.1155/2019/3926175. eCollection 2019.

7.

The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation.

Korth J, Anastasiou OE, Bräsen JH, Brinkhoff A, Lehmann U, Kribben A, Dittmer U, Verheyen J, Wilde B, Ciesek S, Witzke O, Widera M.

J Clin Virol. 2019 Apr;113:14-19. doi: 10.1016/j.jcv.2019.02.002. Epub 2019 Feb 10.

PMID:
30771597
8.

The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients.

Lindemann M, Korth J, Sun M, Xu S, Struve C, Werner K, Dornieden T, Horn PA, Witzke O, Wilde B.

Int J Mol Sci. 2018 Dec 8;19(12). pii: E3945. doi: 10.3390/ijms19123945.

9.

Impact of immune suppressive agents on the BK-Polyomavirus non coding control region.

Korth J, Anastasiou OE, Verheyen J, Dickow J, Sertznig H, Frericks N, Bleekmann B, Kribben A, Brinkhoff A, Wilde B, Sutter K, Dittmer U, Ciesek S, Witzke O, Widera M.

Antiviral Res. 2018 Nov;159:68-76. doi: 10.1016/j.antiviral.2018.09.013. Epub 2018 Sep 27.

PMID:
30268912
10.

Clinical Outcome and Viral Genome Variability of Hepatitis B Virus-Induced Acute Liver Failure.

Anastasiou OE, Widera M, Westhaus S, Timmer L, Korth J, Gerken G, Canbay A, Todt D, Steinmann E, Schwarz T, Timm J, Verheyen J, Ciesek S.

Hepatology. 2019 Mar;69(3):993-1003. doi: 10.1002/hep.30279. Epub 2019 Feb 11.

PMID:
30229977
11.

Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment.

Herrmann A, Sandmann L, Adams O, Herrmann D, Dirks M, Widera M, Westhaus S, Kaiser R, di Cristanziano V, Manns MP, Korth J, Richter N, Anastasiou O, Timm J, von Hahn T, Ciesek S.

J Med Microbiol. 2018 Oct;67(10):1496-1508. doi: 10.1099/jmm.0.000823. Epub 2018 Aug 23.

PMID:
30136921
12.

T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.

Gliga S, Korth J, Krawczyk A, Wilde B, Horn PA, Witzke O, Lindemann M, Fiedler M.

J Clin Virol. 2018 Aug;105:91-96. doi: 10.1016/j.jcv.2018.06.009. Epub 2018 Jun 12.

PMID:
29936407
13.

Pro-Inflammatory Th1 and Th17 Cells Are Suppressed During Human Experimental Endotoxemia Whereas Anti-Inflammatory IL-10 Producing T-Cells Are Unaffected.

Brinkhoff A, Sieberichs A, Engler H, Dolff S, Benson S, Korth J, Schedlowski M, Kribben A, Witzke O, Wilde B.

Front Immunol. 2018 May 18;9:1133. doi: 10.3389/fimmu.2018.01133. eCollection 2018.

14.

The Donor Major Histocompatibility Complex Class I Chain-Related Molecule A Allele rs2596538 G Predicts Cytomegalovirus Viremia in Kidney Transplant Recipients.

Rohn H, Tomoya Michita R, Schwich E, Dolff S, Gäckler A, Trilling M, Le-Trilling VTK, Wilde B, Korth J, Heinemann FM, Horn PA, Kribben A, Witzke O, Rebmann V.

Front Immunol. 2018 May 8;9:917. doi: 10.3389/fimmu.2018.00917. eCollection 2018.

15.

Impact of low-level BK polyomavirus viremia on intermediate-term renal allograft function.

Korth J, Widera M, Dolff S, Guberina H, Bienholz A, Brinkhoff A, Anastasiou OE, Kribben A, Dittmer U, Verheyen J, Wilde B, Witzke O.

Transpl Infect Dis. 2018 Feb;20(1). doi: 10.1111/tid.12817. Epub 2018 Jan 16.

PMID:
29156086
16.

Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA.

Anastasiou OE, Widera M, Korth J, Kefalakes H, Katsounas A, Hilgard G, Gerken G, Canbay A, Ciesek S, Verheyen J.

J Med Virol. 2018 Feb;90(2):282-290. doi: 10.1002/jmv.24942. Epub 2017 Sep 26.

PMID:
28892166
17.

Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies.

Anastasiou OE, Widera M, Verheyen J, Korth J, Gerken G, Helfritz FA, Canbay A, Wedemeyer H, Ciesek S.

J Clin Virol. 2017 Aug;93:46-52. doi: 10.1016/j.jcv.2017.06.001. Epub 2017 Jun 8.

PMID:
28622640
18.

Increased resistance of gram-negative urinary pathogens after kidney transplantation.

Korth J, Kukalla J, Rath PM, Dolff S, Krull M, Guberina H, Bienholz A, Wilde B, Becker S, Ross B, Anastasiou OE, Kribben A, Witzke O.

BMC Nephrol. 2017 May 19;18(1):164. doi: 10.1186/s12882-017-0580-z.

19.

Low transferrin and high ferritin concentrations are associated with worse outcome in acute liver failure.

Anastasiou OE, Kälsch J, Hakmouni M, Kucukoglu O, Heider D, Korth J, Manka P, Sowa JP, Bechmann L, Saner FH, Paul A, Gerken G, Baba HA, Canbay A.

Liver Int. 2017 Jul;37(7):1032-1041. doi: 10.1111/liv.13369. Epub 2017 Feb 12.

PMID:
28109050
20.

Performance and Utility of Transient Elastography and Non-Invasive Markers of Liver Fiibrosis in Patients with Autoimmune Hepatitis: A Single Centre Experience.

E Anastasiou O, Büchter M, A Baba H, Korth J, Canbay A, Gerken G, Kahraman A.

Hepat Mon. 2016 Oct 31;16(11):e40737. doi: 10.5812/hepatmon.40737. eCollection 2016 Nov.

Supplemental Content

Loading ...
Support Center